Mylan $7.2 billion bid for Meda

11/2/2016

Public acquisition

Value:

$ 7.2 billion

Status:

Completed

Date:

11/2/2016

Overview:

Mylan has made a $7.2 billion bid for Meda.
Meda is an international pharmaceutical company listed on the Nasdaq OMX Stockholm.
Mylan is a global pharmaceutical company listed on the Nasdaq and Tel Aviv Stock Exchange.
The deal is being financed via a bridge credit facility arranged by Deutsche Bank and Goldman Sachs.
Centerview Partners acted Mylan's financial adviser. Rothschild & Co acted as Meda's financial adviser.
The deal comes shortly after Mylan gave up its pursuit of Perrigo.

Rani Mehta - Journalist

Jurisdictions:

United States
Netherlands
Sweden

Deal type:

Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:

Cleary Gottlieb Steen & Hamilton

Party: Meda (Target)

Cravath Swaine & Moore

Party: Mylan (Acquirer)

Lawyers: Aaron Gruber, George Zobitz, Mark Greene

Mannheimer Swartling

Party: Meda (Target)

Lawyers: Eva Hägg, Patrik Marcelius

NautaDutilh

Party: Mylan (Acquirer)

Lawyer: Paul van der Bijl

Vinge

Party: Mylan (Acquirer)

Lawyer: Erik Sjöman

Related deals